All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2020-09-09T06:48:14.000Z

Practice-changing abstracts at #ASCO20 and EHA 2020

By Claire Baker, Amalia Zachariadis
Featured
Mohamad Mohty
Sep 9, 2020
Share:

Bookmark this article

GvHD Hub Co-Chair Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne Université, Paris, FR, provides an overview of the practice-changing abstracts from this year's virtual American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Annual Congress.

Practice-changing abstracts at ASCO and EHA 2020

Mohamad Mohty highlights 2020 as a major year for GvHD. In particular, 2020 saw the publication of the first positive phase III trial for steroid-refractory GvHD. 

More about...
Acute graft-versus-host diseaseASCO 2020EHA 2020Graft-versus-host diseaseREACH2RuxolitinibSteroid-refractory GvHD

Your opinion matters

HCPs, what is your preferred format for educational content on the GvHD Hub?
9 votes - 13 days left ...

Related articles

Add bookmark

Updated results from REACH2: Ruxolitinib for steroid-refractory acute GvHD

As previously reported on the GvHD Hub, the initial data from the phase III REACH2 trial uncovered the potential benefit of ruxolitinib over best available treatment (BAT) for...

Apr 8, 2021
Add bookmark

Updated results from REACH2: Ruxolitinib for steroid-refractory acute GvHD

As previously reported on the GvHD Hub, the initial data from the phase III REACH2 trial uncovered the potential benefit of...

Apr 8, 2021
Add bookmark

REACH2: What patients with steroid-refractory acute GvHD respond best to ruxolitinib?

An interview from the 25th Congress of the EHA with Robert Zeiser, Medical Center – University of Freiburg, Freiburg, DE, who discussed the REACH2 clinical trial.

Jun 18, 2020
Add bookmark

REACH2: What patients with steroid-refractory acute GvHD respond best to ruxolitinib?

An interview from the 25th Congress of the EHA with Robert Zeiser, Medical Center – University of Freiburg,...

Jun 18, 2020

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox